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ABSTRACT
Objective: To formulate and evaluate an extended-release (ER) tablet of a new molecule, 2-amino-4-(4-bromophenyl)-7-hydroxy-4H-chromene-3-
carbonitrile using a combination of two polymers (hydroxypropyl methyl cellulose [HPMC] K100 and HPMC phthalate) which control the rate and 
degree of the drug release through 12 hrs period and protect the drug release from acidic pH.
Methods: Five batches of tablets (4HC1, 4HC2, 4HC3, 4HC4, 4HC5) were produced by direct compression method. Morphological evaluation of the 
powder blend was carried out by differential scanning calorimetry and Powered X-ray diffractometry. The evaluation studies such as flow properties, 
hardness, friability, drug content, and release study were conducted according to pharmacopoeial standards.
Results: The physicochemical characteristics of all the granules and tablets were generally satisfactory. The drug release followed zero order, Higuchi 
model kinetics with diffusion and dissolution mediated mechanism. Tablets were evaluated for physicochemical parameters and promising. Stability 
studies indicated the dosage form is stable for 3 months at accelerated conditions.
Conclusion: From the results received from all test, it was concluded that formulation 4HC4 are the most suitable choice for developing 12 hrs ER 
tablets. This finding reveals that a particular concentration of HPMC K100 was capable of producing ER.
Keywords: Chromene derivative, Extended-release, Hydroxypropyl methylcellulose phthalate, Hydroxypropyl methylcellulose K100.
INTRODUCTION
Inflammatory bowel disease (IBD) is a chronic gastrointestinal (GI) 
disorder which includes ulcerative colitis and Crohns disease. The exact 
cause of disease is undefined; certain factors have been suggested to 
play a role, such as genetics, microbiome, environmental stress, and 
immune dysfunction. Current therapeutic agents are limited for use 
in IBDs as they are generally designed to achieve systemic delivery of 
therapeutics, which results in adverse effects and toxicity following 
distribution of drug around the body. Oral formulations achieving a 
localized effect are preferred in rational drug delivery design for IBD. 
Current therapeutic approaches specifically indicated for IBD rely on 
conventional dosage forms such as delayed or extended release (ER) 
mechanisms [1,2]. Conventional drug delivery systems are failed to 
treat such diseases because the drugs do not offer site-specific drug 
delivery. Hence, the site specific delivery of drugs is promising tool for 
such diseases whereby minimizing the side effects that occur because 
of unnecessary systemic absorption [3].





ER dosage forms are designed to achieve a prolonged therapeutic 
effect by continuously releasing the drug over an extended period after 
administration of a single dose [6,7]. The advantages of ER dosage forms 
over conventional forms include the less fluctuation in drug blood levels, 
frequency reduction in dosing, enhanced convenience, and compliance, 
reduction in adverse effects and reduction in overall health-care costs.
2-amino-4H-chromene derivatives with nitrile functionality have 
wide	 application	 in	 tumor	 necrosis	 factor	 α	 (TNF-α)	 mediated	
disease such as IBD, rheumatoid arthritis, and other inflammation 
mediated disease [8-10]. Chromene moiety represents a novel class 
of	TNF-α	 inhibitor,	one	of	 the	best	examples	 in	 this	 class	 is	2-amino-
4-(4-bromophenyl)-7-hydroxy-4H-chromene-3-carbonitrile is a novel 
chromene derivative (Fig. 1) [11]. The compound is synthesized by 
condensation reaction of malononitrile, substituted aldehyde, and 
activated phenol in the presence of an organic base (pyridine) for 
several [12,13]. The solubility of the synthesized compound enhanced 
by complexation technique using hydroxypropyl beta cyclodextrin.
The main objective of the present study to formulate site-specific drug 
delivery system containing a chromene derivative using polymers like 
hydroxypropyl methylcellulose (HPMC) phthalate and HPMC K100 and 
evaluates its physical parameters and in vitro drug release studies. The 
aim of present study was to formulate and evaluate an ER tablet of a 
new molecule 2-amino-4-(4-bromophenyl)-7-hydroxy-4H-chromene-
3-carbonitrile using a combination of two polymers (HPMC K100 and 
HPMC phthalate). Which control the rate and degree of the drug release 
through 12 hrs period and protect the drug release from acidic pH. Site-
specific drug delivery devices are provided with a pH-sensitive polymer. 
Many studies have indicated the considerable variation in pH gradient 
in the GI tract; therefore, completely depending on the pH sensitivity 
of the polymer. In this research work, the ER tablets were compressed 
with varying proportions of HPMC phthalate and HPMC K100 and 
studied in vitro for their release profile in various pH conditions. The 
drug release kinetics was studied by using various kinetic studies 
available, such as Higuchi, Korsemeyer–Peppas, zero order, and first 
order kinetics. The results of the overall study, release kinetics, and 
mechanism of drug release were elaborately discussed in this work.
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METHODS
2-amino-4-(4-bromophenyl)-7-hydroxy-4H-chromene-3-carbonitrile 
is synthesized in our laboratory. HPMC K100, microcrystalline 
cellulose 102 (MCC 102), lactose, aerosil, and magnesium stearate were 
purchased from Yarrow chem products Mumbai. HPMC phthalate was 
purchased from Colorcon Asia Pvt. Ltd. Goa.
Calibration graph of synthesized drug
Weigh 10 mg of synthesized compound; add sufficient quantity of methanol 
to	produce	a	stock	solution	of	100	μg/ml.	From	the	standard	stock	solution,	
dilutions	 were	 made	 into	 the	 concentration	 of	 10-50	 μg/ml.	 Take	 the	
absorbance at 318 nm on ultraviolet spectrophotometer against blank.
Preparation of ER tablet
Direct compression method was used to prepare ER tablets of newly 
synthesized compound. Required amount of the, synthesized drug, MCC 
102, lactose, polymers were taken and were sieved through #44. It was 
then mixed with magnesium stearate and aerosil which was previously 
sieved using #60. Five different set of tablets were prepared on rotary 
compression machine [14,15].
Evaluation studies
The granules were evaluated for various physicochemical parameters 
including angle of repose, bulk density, tap density, compressibility 
index and Hausner ratio. The prepared powder blend was characterized 
by differential scanning calorimetry (DSC) and Powered X-ray 
diffractometery (PXRD).
The compressed tablets were characterized by their physicochemical 
parameters. The hardness of the tablets was tested using Monsanto tablet 
hardness tester. The average weight was also determined as per (Indian 
Pharmacopoeia [IP]). 10 tablets from each batch of formulations were 
selected randomly, and thickness of tablets was measured using vernier 
caliper. The Friability was determined in roche friabilator. Friability was 
calculated as a percentage of weight loss after 100 rotations (IP).
Drug release study
In vitro	 dissolution	 studies	 were	 performed	 using	 the	 United	 States	
Pharmacopeia	(USP)	dissolution	apparatus	II.	The	volume	of	dissolution	
medium was 900 ml, and it was maintained at 37±0.5°C and stirred at 
paddle speed of 50 rpm. Simulated gastric fluid (pH 1.2) and simulated 
intestinal fluid (pH 7.4), prepared according to standard monograph 
without enzymes were used as dissolution media. Dissolution test was 
run for 1 hr in simulated gastric fluid and subsequently on stimulated 
intestinal fluid. 5 ml of samples were collected at time intervals of 
5, 10, 15, 20, 30, 45, 60 minutes and replaced by the equal amount 
of dissolution medium to maintain a constant volume. Samples were 
analyzed spectrophotometrically at 318 nm to determine the amount of 
drug released from which the percentage drug release was calculated.
Stability study
The stability studies were performed both at room temperature and 
accelerated stability study conditions. The prepared formulations were 
stored at 40±2°C and 75±5°C relative humidity in a stability chamber for 
3 months and observed the physical changes occurred in each month.
RESULTS
Calibration curve
Fig. 2 indicates the standard calibration curve of synthesized compound. 
The absorbance of the different concentration of synthesized drug was 
measured	using	methanol	as	a	blank	(λmax=318 nm), and the correlation 
coefficient (R2) was found to be 0.994.
Evaluation of granules
All the data obtained were compared with the standard value mentioned 
in IP. Based on the criteria, it was found that the all the ER tablets have 
well flow properties and better compressibility. Table 2 represents the 
Physical characteristics of the prepared granules.
The bulk density of the granules ranged from 0.57 to 0.62 g/ml and 
tapped density from 0.58 to 0.67 g/ml. The angle of repose of the 
granules was in the range of 27.94-32.15°.
The	compressibility	(Carr’s	 index)	 for	all	 the	 formulations	was	≤10%	
while Hausner ratio was in the range 1.00-1.11.
Physicochemical characteristics of prepared formulations
Table 3 indicates the results of the various physicochemical tests 
(hardness, friability, and drug content) performed on the tablet 
formulations.
The hardness of the prepared tablets was in the range 5.1-5.8 kg/cm2. All 
the	formulations	showed	<1%	friability	which	is	within	the	prescribed	
limit. Drug content was uniform within each batch and ranged from 
97.22%	to	98.54%	of	the	theoretical	value.
Characterization of ER tablet by DSC and PXRD
The thermal behavior of optimized formula and powder blend was 
studied using DSC. The thermogram of the powder blend shows a 
characteristic peak of excipients in Figs. 3 and 4.
PXRD
The PXRD pattern of optimized formulation displayed intense and sharp 
peaks at 12.40, 19.585° with high intensity. The PXRD were shown in 
Figs. 5 and 6. The lack of crystallinity in the formulation might be due 
to solubilization of synthesized molecule in inclusion complex which is 
absorbed into carrier. This suggested although some crystalline signals 
of physical mixture were still detectable in the optimized formulation.
In vitro drug release study
The in vitro drug release results for the 5 different formulations are 
shown in Fig. 7. From the dissolution study, it was observed that a 
formulation 4HC4 has the highest release compared to other batches in 
terms of both the rate and extent of the drug released.
It was concluded that HPMC K100 can be used as an effective extend 
release polymer to retard the release of drug. The best ER of tablet was 
obtained from the blend of drug and HPMC K100 in 1:1.8 ratios.
Fig. 1: 2-amino-4-(4-bromophenyl)-7-hydroxy-4H-chromene-3-
carbonitrile
Ingredients (mg) 4HC1 4HC2 4HC3 4HC4 4HC5
Drug 30 30 30 30 30
HPMC K100 15 30 45 53.136 60
MCC 102 64.05 25.92 25.92 25.92 31.784
Lactose 54.75 77.5 69.75 54.75 54.75
Hypromellose 
phthalate
52 52 52 52 52
Magnesium stearate 0.81 0.81 0.81 0.81 0.81
Aerosil 0.81 0.81 0.81 0.81 0.81
Drug:	Synthesized	drug-HPβCD	complex,	HPMC	K100:	Hydroxypropyl	
methylcellulose, MCC 102: Microcrystalline cellulose 102
Table 1: Formula for 1 tablet with formulation code
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Mathematical modeling of kinetics
The optimized formulation 4HC4 followed zero order kinetic 
mechanism. In addition, Higuchi as best fitted model, non-Fickian 
diffusion as the corresponding values of n is lower than or equal to the 
standard value of Fickian release behavior. Thus, the results point out 
the mechanistic diffusion and dissolution phenomena. Table 5 mentions 
kinetic modeling from the optimized formulation.
Stability study
The physical parameters of tablet kept for stability study were evaluated 
and compared with the initial values of any significant changes. Results 
which are shown in Table 5. Stability studies were done for 3 months, 
and it was noted that surface of tablet free from microbial or fungal 
growth	 or	 bad	 order.	 The	 tablets	 showed	 not	 <98.5%	 drug	 content	
and all the physical parameters within the specified limit there was no 
significance in the values.
DISCUSSION
In the presented study, ER tablets of synthesized compound were 
prepared for optimized drug release patterns during in vitro 
dissolution studies. Various formulations were prepared containing 
varying amount of polymer to see the effect of polymer concentration 
on drug release rates. The prepared mixed powder was physically 
evaluated with some parameters. The average compressibility index 
of	 the	 mixed	 powder	 of	 all	 the	 formulations	 was	 ≤10.44±0.52,	 and	
average angle of repose was in the range of 27.94-32.15° which 
indicates that the mixed powder was having good flow properties. 
The prepared ER tablets were evaluated for some physical tests. 
The average hardness of ER tablets was in the range 5.1-5.8 kg/cm2, 
average	 friability	was	<1%	and	average	 thickness	were	 in	 the	 range	
Table 2: Physical characteristics of powder mixtures
Formulations Angle of 
repose (°)
Bulk density (g/ml) Tapped density (g/ml) Carr’s index (%) Hausner’s ratio
4HC1 32.15±1.04 0.574±0.013 0.656±0.018 9.54±0.58 1.023±0.010
4HC2 29.16±1.06 0.577±0.010 0.612±0.017 9.07±0.54 1.034±0.012
4HC3 28.23±1.07 0.573±0.014 0.589±0.019 9.84±0.63 1.048±0.015
4HC4 27.45±1.08 0.611±0.015 0.627±0.013 10.44±0.52 1.037±0.011
4HC5 27.94±1.04 0.628±0.013 0.677±0.017 9.04±0.67 1.032±0.015













4HC1 5.5±0.04 4.15±0.11 0.49±0.068 168.42±0.035 97.22±0.24
4HC2 5.8±0.35 4.27±0.10 0.45±0.0.016 167.54±0.741 98.54±0.32
4HC3 5.1±0.21 4.26±0.13 0.38±0.073 167.66±0.137 98.42±0.35
4HC4 5.7±0.37 4.23±0.13 0.55±0.01 167±0.212 97.68±0.47
4HC5 5.5±0.39 4.52±0.17 0.44±0.16 166±0.389 97.51±0.28
ER: Extended release
Fig. 2: Calibration graph of synthesized drug
Time (hrs) Cumulative amount of percentage drug release
4HC1 4HC2 4HC3 4HC4 4HC5
0 (minute) 0 0 0 0 0
5 (minutes) 2.02±0.416 1.97±0.720 1.55±0.08 3.80±0.006 4.001±0.271
10 (minutes) 6.74±0.423 4.18±0.201 3.99±0.672 9.23±0.334 8.63±0.298
15 (minutes) 9.65±0.296 6.11±0.03 9.17±0.543 18.34±0.543 16.72±0.373
30 (minutes) 15.25±0.33 8.911±0.85 15.63±0.55 21.10±0.339 20.11±0.127
45 (minutes) 18.43±0.21 14.23±0.8 18.076±0.1 23.65±0.432 23.66±1.763
1 (hr) 22.06±0.42 19.93±0.07 20.31±0.06 28.36±0.003 26.78±0.765
2 (hrs) 27.26±0.21 26.35±0.04 28.73±0.03 39.98±0.110 28.99±0.109
3 (hrs) 31.54±0.223 31.43±0.333 36.76±0.438 49.47±0.22 33.42±0.080
4 (hrs) 44.32±0.224 36.78±0.304 45.33±0.866 61.754±0.010 39.57±0.117
6 (hrs) 49.52±0.267 39.32±0.317 53.59±0.543 72.47±0.007 47.04±0.103
7 (hrs) 53.77±0.287 51.58±0.264 59.34±0.414 78.32±0.372 56.45±0.677
8 (hrs) 57.53±0.246 59.41±0.266 65.44±0.810 83.66±0.507 63.33±0.257
9 (hrs) 64.78±0.292 65.98±0.711 76.83±0.197 85.002±0.611 69.05±1.120
10 (hrs) 70.81±0.518 71.77±0.681 81.55±0.185 88.43±0.2469 78.11±0.9841
11 (hrs) 76.42±0.293 77.18±0.281 83.67±0.912 90.11±1.223 80.42±0.7935
12 (hrs) 83.28±0.237 81.72±0.623 80.39±0.864 90.88±0.267 76.02±0.4586
ER: Extended release
Table 4: In vitro drug release profile of prepared ER tablets
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of	4.15±0.11-4.52±0.17	mm	which	was	all	 in	acceptable	USP	ranges.	
The release of drug from ER tablets prepared at 5 different D: P ratios 
and the affects of different coexcipients on drug release rates can be 
seen	from	the	Fig.	7.	It	was	observed	that	about	90%	drug	was	released	
in 12 hrs from the preparations prepared at D: P ratio 1:1.8 (4HC4), 
while the most extended drug release profiles were observed from the 
formulation prepared at D: P ratio 1:1.8 (4HC4).
Different kinetic models were applied to the optimized formulation 
and observed that the 4HC$ followed zero order kinetic model. The 
best linearity was found in Higuchi model (where n=1.11 is the release 
exponent); applicability of data indicating non-Fickian diffusion.
The stability study for the selected formulation of 4HC4 was performed 
as per ICH guidelines. Stability studies were done for 3 months, and it 
Fig. 3: Differential scanning calorimetry thermogram of physical mixture
Fig. 4: Differential scanning calorimetry thermogram of optimized formulation
Fig. 5: Powered X-ray diffractometery of physical mixture
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was noted that surface of tablet free from microbial or fungal growth 
or	bad	order.	The	tablets	showed	not	<98.5%	drug	content	and	all	the	
physical parameters within the specified limit there was no significance 
in the values.
CONCLUSION
ER tablet containing chromene derivative was prepared successfully 
by direct compression method. All the tablets possessed good physical 
property. Among all the formulations, the formulation which prepared 
using HPMC K100 found to be effective in controlling the drug release 
up to 12 hrs. Stability studies revealed that there was no significant 
change in appearance, drug content and in vitro release of selected 
formulation (4HC4). It was observed that all batches gave the release by 
the diffusion-dissolution controlled mechanism. The dispersion of the 
Fig. 6: Powered X-ray diffractometery of optimized formulation
Fig. 7: In vitro dissolution data of extended release tablets
Fig. 8: Percentage cumulative drug release v/s time (zero order 
model) from the optimized formulation
Fig. 9: Log cumulative drug release v/s time (first order model) 
from the optimized formulation
Fig. 11: Log cumulative drug release v/s log time 
(Korsmeyer–Peppas model) from the optimized formulation
Fig. 10: Percentage cumulative drug release v/s square root time 
(Higuchi model) from the optimized formulation
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drug in the polymer network altered its dissolution profile at pH 7.2, 
thus making it possible to obtain a gradual and prolonged release, and 
to modulate the release pattern.
Our preliminary findings on optimized ER tablets can be served for 
further investigation to assess the efficacy of the formulation by in vitro 
and in vivo IBD model.
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Months Hardness (kg/cm2) Friability (% loss) Weight variation (mg) Drug content (%) Physical appearance
Initial 3.1±0.341 0.402±0.12 167±0.40 98.33±1.26 White
After 2 week 3.1±0.21 0.48±0.17 167±0.30 98.57±0.30 White
After 1 month 3.2±0.35 0.46±0.20 166±0.22 98.57±0.36 White
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Table 6: Physical parameters of ER tablets (formula 4HC4 kept under stability study)
